Form 4: Akebia CEO Granted Significant Equity Awards

Akebia Therapeutics CEO and President John P. Butler was granted 743,000 restricted stock units and 1,115,000 stock options, effective January 30, 2026.

Summary

• John P. Butler, CEO and President, and a Director of Akebia Therapeutics, Inc. (AKBA), reported changes in beneficial ownership.
• On January 30, 2026, Mr. Butler was granted 743,000 shares of Common Stock in the form of restricted stock units (RSUs) under the Issuer's 2023 Stock Incentive Plan, as amended, with a price of $0.00.
• These RSUs will vest one-third on each of the first, second, and third anniversaries of the grant date, contingent on continued service.
• Additionally, on January 30, 2026, Mr. Butler was granted 1,115,000 stock options with an exercise price of $1.41, also under the Issuer's 2023 Stock Incentive Plan, as amended, with a price of $0.00.
• These options will vest over four years: 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments thereafter, subject to continued service.
• The stock options have an expiration date of January 30, 2036.
• Following these transactions, Mr. Butler directly beneficially owns 3,463,849 shares of Common Stock and 1,115,000 derivative securities (stock options).
• He also indirectly beneficially owns 159,928 shares of Common Stock held by the Dorothy Butler Revocable Trust November 20, 2007.
• The reported beneficial ownership includes 159,928 shares previously held by John Butler 2019 GRAT, and 1,500 shares purchased on June 30, 2025, and 1,500 shares purchased on December 31, 2025, under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for management alignment and retention, as significant equity grants incentivize the CEO's long-term commitment and performance, which can benefit shareholders.

Positives

• The significant grant of 743,000 restricted stock units and 1,115,000 stock options aligns the CEO's long-term interests with those of shareholders.
• The multi-year vesting schedules for both RSUs and options incentivize the CEO's continued service and focus on sustained company performance.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged and structured approach to equity compensation.

Future Outlook

The restricted stock units will vest one-third on each of the first, second, and third anniversaries of the grant date. The stock options will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments thereafter. All vesting is subject to the reporting person's continued service with the Issuer.

Industry Context

StockSavvy.ai notes that significant equity grants to top executives are a common practice to align interests and incentivize performance in the biotech sector, particularly for companies like Akebia Therapeutics, where long-term drug development cycles necessitate sustained leadership commitment.

Comparison to Industry Standards

• StockSavvy.ai observes that equity grants of this magnitude for a CEO in a biotech company of Akebia's size are generally within industry norms for executive compensation, aiming to retain key talent and drive long-term value creation.
• Comparable executive compensation packages in the biotech industry often include a mix of base salary, performance-based cash bonuses, and substantial equity awards (RSUs and options) to ensure executives are incentivized by the company's stock performance over several years.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term company performance and shareholder value creation.
• Employees: No direct impact mentioned, but a stable, incentivized leadership can contribute to overall company stability.
• Management: The CEO receives significant long-term incentives, enhancing retention and motivation.

Next Steps

• Vesting of 743,000 restricted stock units on the first, second, and third anniversaries of January 30, 2026.
• Vesting of 1,115,000 stock options, with 25% on the first anniversary of January 30, 2026, and the remaining 75% in equal quarterly installments thereafter.

Key Dates

Recommendation

While the significant equity grants align management interests with shareholders, this Form 4 primarily reports compensation and does not provide new operational or financial performance data to warrant a change from a 'hold' position without further analysis of the company's fundamentals. The future-dated transactions are part of a pre-existing compensation plan.

Keywords

Akebia Therapeutics, AKBA, John P. Butler, CEO compensation, restricted stock units, stock options, insider ownership, equity grants, 10b5-1 plan, executive compensation